|
Published by: Espicom Healthcare Intelligence
Published: Aug. 17, 2006 - 96 Pages
Table of Contents
- Foreword
- Executive Summary
- What are Asthma and COPD?
- Morbidity and Mortality
- Diagnosis and Treatment
- Asthma Management
- COPD Management
- Pharmacotherapy
- Current Market Leaders
- Drugs in the Pipeline
- Competitor Ratio Analysis
- Short-Acting Beta-2 Agonists
- Xopenex (levalbuterol)
- Sales Forecast
- Patent Challenges
- Clinical Trials
- Xopenex versus racemic albuterol in COPD
- Xopenex HFA study
- Xopenex in the emergency room
- Inhaled Corticosteroids
- Flixotide/Flovent (fluticasone propionate)
- Sales Forecasts
- Clinical Trials
- Pulmicort (budesonide)
- Sales Forecast
- Patent Challenge
- Clinical Trials
- START - budesonide during pregnancy
- START - budesonide in children with mild persistent asthma
- START - safety outcome data
- EUROSCOP
- Long-term data from early intervention study in Finland
- Asmanex (mometasone furoate)
- Sales Forecasts and Assumptions
- Competitor Ratio Analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within marketplace
- Risks associated with drug development in therapeutic class
- Clinical Trials
- Patients previously maintained on bronchodilators alone
- Patients previously maintained on inhaled corticosteroids
- Patients previously maintained on oral corticosteroids
- Alvesco (ciclesonide)
- Sales Forecast and Assumptions
- Competitor Ratio Analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within marketplace
- Risks associated with drug development in therapeutic class
- Clinical trials
- Ciclesonide versus fluticasone propionate
- Low incidence of oropharyngeal side effects
- Ciclesonide versus budesonide and fluticasone
- Intranasal formulation
- Ciclesonide versus budesonide
- Muscarinic Antagonists
- Spiriva (tiotropium)
- Sales Forecast and Assumptions
- Competitor Ratio Analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within marketplace
- Risks associated with drug development in therapeutic class
- Clinical Trials
- Pooled Studies
- Study on COPD patients in France
- Spiriva+formoterol versus salmeterol+fluticasone propionate
- UPLIFT
- TIPHON
- Combination Therapy
- Seretide/Advair (salmeterol+fluticasone propionate)
- Sales Forecasts
- Patent Challenge
- Safety Issues
- Clinical Trials: COPD
- TORCH
- TRISTAN
- Clinical Trials: Asthma
- Biopsy Study in Moderate Asthma
- EXCEL
- GOAL
- Advair versus montelukast
- Symbicort (budesonide+formoterol)
- Sales Forecast
- European patent challenge
- Clinical Trials: COPD
- Calverly et al.
- Clinical Trials: Asthma
- SUND
- STAY
- Head to head study: Symbicort Turbuhaler versus Seretide (salmeterol+fluticasone)
- Clinical Trials: Asthma+COPD
- ASSURE
- Leukotriene Receptor Antagonists
- Singulair (montelukast)
- Sales Forecast
- Clinical Trials
- PREVIA
- Anti-Immunoglobulin E Therapy
- Xolair (omalizumab)
- Sales Forecast and Assumptions
- Competitor Ratio Analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within marketplace
- Risks associated with drug development in therapeutic class
- Clinical Trials
- Long-term data
- Pooled study data
- Drugs in Development
- PDE-IV Inhibitors
- Ariflo (cilomilast)
- Sales Forecasts and Assumptions
- Competitor Ratio Analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within marketplace
- Risks associated with drug development in therapeutic class
- Clinical trials
- Daxas (roflumilast)
- Sales Forecasts and Assumptions
- Competitor Ratio Analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within marketplace
- Risks associated with drug development in therapeutic class
- Clinical Trials
- Efficacy & safety study in COPD
- RATIO/M2-112
- RECORD
- Other studies
- Long-Acting Beta Agonists
- Arformoterol
- Sales Forecasts and Assumptions
- Competitor Ratio Analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within marketplace
- Risks associated with drug development in therapeutic class
- Clinical Trials
- Indacaterol
- Sales Forecast and Assumptions
- Competitor Ratio Analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within marketplace
- Risks associated with drug development in therapeutic class
- Clinical Trials
- GSK 159797
- Sales Forecasts and Assumptions
- Competitor Ratio Analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within marketplace
- Risks associated with drug development in therapeutic class
- Clinical Trials
- Long-Acting Muscarinic Antagonists
- NVA237
- Sales Forecast and Assumptions
- Competitor Ratio Analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within marketplace
- Risks associated with drug development in therapeutic class
- Clinical Trials
- SOURCES
- Espicom Sources
- Others
- List of Tables
- Deaths from COPD and Asthma in Major Markets, 2002
- Deaths from COPD and Asthma in the USA, 2002
- GINA Stepwise Approach to Asthma Medication
- GOLD Therapy Recommendations for COPD
- Leading Asthma and COPD Therapies by Sales Value, 2004-2005 (US$ Million)
- US Patent Expiry for Major Asthma and COPD Therapies
- Launched Products in Development
- Novel Drugs in Development
- Competitor Ratio Analysis Summary
- Xopenex Sales, 2001-2005 (US$ Million)
- Flixotide/Flovent Sales, 2001-2005 (£ & US$ Million)
- Pulmicort Sales, 2001-2005 (US$ Million)
- Spiriva Sales, 2002-2005 (Euros & US$ Million)
- Advair/Seretide Sales, 2001-2005 (£ & US$ Million)
- Symbicort Sales, 2001-2005 (US$ Million)
- Singulair Sales, 2002-2005 (US$ Million)
- Xolair Sales, 2003-2005 (US$ Million)
- Xolair Projected Sales, 2005-2011 (US$ Million)
- List of Figures
- Novel Drugs in Clinical Development by Activity
- Xopenex Projected Sales, 2005-2011 (US$ Million)
- Flixotide/Flovent Projected Sales, 2005-2011 (US$ Million)
- Pulmicort Projected Sales, 2005-2011 (US$ Million)
- Asmanex Twisthaler Projected Sales, 2005-2011 (US$ Million)
- Alvesco Projected Sales, 2005-2012 (US$ Million)
- Spiriva Projected Sales, 2005-2011 (US$ Million)
- Seretide/Advair Projected Sales, 2005-2011 (US$ Million)
- Symbicort Projected Sales, 2005-2011 (US$ Million)
- Singulair Projected Sales, 2005-2011 (US$ Million)
- Ariflo Projected Sales, 2007-2012 (US$ Million)
- Daxas Projected Sales, 2008-2013 (US$ Million)
- Arformoterol Projected Sales, 2007-2012 (US$ Million)
- Indacaterol Projected Sales, 2009-2014 (US$ Million)
- GSK 159797 Projected Sales, 2008-2013 (US$ Million)
- NVA237 Projected Sales, 2009-2014 (US$ Million)
AbstractA fast growing sector with strong products and players - but what will the COPD/Asthma landscape look like 5 years from now?
The global asthma and COPD market is currently worth around US$20 billion. The top twelve pharmaceutical products by value had combined global sales of US$15.7 billion in 2005. Six brands had sales in excess of US$1 billion. Combined sales of the top ten products were 21.1% higher than in 2004.
A number of older therapies, for asthma in particular, are widely available generically and there is fierce competition in the market. The asthma market accounts for the majority of the total and is valued at around US$15 billion. The COPD market is currently valued at US$4 - US$5 billion and is set to double in the next five years.
Future market growth will be driven by increasing disease awareness, an increasing patient pool, both in the paediatric asthma sector and the ageing population susceptible to COPD, and the launch of newer, more expensive therapies targeting areas of high unmet clinical need. These will be offset to some extent by the launch of new generics and the sales erosion of monotherapies by combination products.
Providing
- Product/Market Forecast by value 2006/2011 for current and future therapies
- 15 key products assessed
- Market Context
- Competitive Evaluation
- Research Reviews
Covering
- Beta-2 Agonists
- Inhaled Corticosteroids
- Combination Therapies
- Leukotrine Receptor Antagonists
- Anti-Immunoglobulin E Therapy
- Muscarinic Antagonists/ Anticholinergics
- PDE-IV Inhibitors
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
|
About MarketResearch.com
MarketResearch.com is an online aggregator selling over 300,000 market research reports,
company profiles and country profiles from over 700 research firms. Our reports will
provide you with the critical business and competitive intelligence you need for strategic planning and marketing
research. Coverage includes the US, UK, Europe, Asia and global markets.
© MarketResearch.com 2012
|
